REDWOOD CITY, Calif., July 10, 2012 (GLOBE NEWSWIRE) -- The newest generation of myoscience's novel device technology has received FDA clearance for the treatment of pain.
myoscience's patented technology precisely delivers cold to targeted nerves. The cold induces a hibernating state resulting in a temporary interruption of nerve signaling to sensory receptors or muscle tissue. The device uses the power of cold to achieve an immediate result with nothing left behind in the patient. The myoscience device received CE approval and a medical device license from Health Canada in 2011.
The hand-held device is intended for use in the physician's office and represents a breakthrough advance in the treatment of pain. The myoscience technology can address multiple indications in a targeted treatment with no systemic side effects or addictive potential.
"FDA clearance for our device in the US provides myoscience with a platform technology on which to grow our company by addressing further indications and an expanding geography," said Clint Carnell, Chief Executive Officer of myoscience.
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the pre-eminent treatment for nerves. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581